- Aetna coverage for Wegovy and Zepbound varies by plan — some plans cover one, both, or neither
- Most Aetna plans require prior authorization including documented BMI and comorbidities
- Additional FDA indications — cardiovascular risk reduction for Wegovy and sleep apnea for Zepbound — may open alternative coverage pathways
- PEAK’s insurance team verifies your benefits and handles prior authorization before your first visit
Note: PEAK accepts Aetna commercial plans. We do not accept Aetna Medicare Advantage plans.
The short answer
Some Aetna plans cover Wegovy (semaglutide), Zepbound (tirzepatide), or both for weight loss — but many do not. Coverage depends entirely on your specific plan, who your employer is, and whether anti-obesity medications are included in your formulary.
There is no single “Aetna policy” on these medications. Aetna administers hundreds of different plan designs, each with its own formulary, exclusion list, and prior authorization requirements. Two people with Aetna cards can have completely different coverage — and a plan that covers Wegovy may not cover Zepbound, or vice versa.
Wegovy (semaglutide, by Novo Nordisk) and Zepbound (tirzepatide, by Eli Lilly) are both FDA-approved for chronic weight management but work through different mechanisms and sit on different formulary tiers. Your Aetna plan evaluates each separately, so being denied for one does not necessarily mean the other is off the table.
Plans that may cover these medications
Aetna plan types that are more likely to include Wegovy or Zepbound coverage:
- Large employer-sponsored plans — These are the most common source of coverage. Employers choose whether to include anti-obesity medications in their formulary. Some have added Wegovy, Zepbound, or both; many have not.
- Self-funded employer plans administered by Aetna — The employer, not Aetna, makes the formulary decisions. Coverage is entirely up to the employer’s benefits team.
- Aetna Medicare Advantage plans — Some Medicare Advantage plans have started covering GLP-1 medications for weight loss, though this is still uncommon.
- ACA marketplace plans — Coverage varies by state and plan tier. Anti-obesity medications are not required to be covered under the ACA essential health benefits.
Aetna individual plans, short-term plans, and plans with explicit “weight loss medication exclusions” typically do not cover Wegovy or Zepbound. If your plan documents include a weight loss plan exclusion, both medications will generally be denied regardless of medical necessity.
Prior authorization requirements
Even when Aetna covers Wegovy or Zepbound, you will almost certainly need prior authorization (PA). This is a process where your prescribing clinician submits documentation to Aetna proving that the medication is medically necessary for you. The PA criteria are similar for both medications.
Aetna’s typical PA requirements for Wegovy and Zepbound include:
- Documented BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea)
- Evidence of participation in a structured weight management program (diet, exercise, behavioral counseling) for a minimum period — often 3 to 6 months
- Documentation that other weight loss interventions have been attempted
- Prescriber must be a physician, NP, or PA with appropriate prescribing authority
Prior authorization is not a denial — it is a documentation requirement. The better the documentation, the higher the approval rate.
At PEAK, our clinical team documents everything from your first visit with PA requirements in mind. We know what Aetna looks for because we submit these requests routinely.
Additional coverage pathways
Both Wegovy and Zepbound have FDA-approved indications beyond weight management, and these can create alternative routes to insurance coverage.
Zepbound and obstructive sleep apnea
In late 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. If you have a documented sleep apnea diagnosis confirmed by a sleep study, your clinician may be able to submit the prior authorization under the OSA indication. Some Aetna plans that exclude weight loss medications may still cover medications prescribed for sleep apnea.
Wegovy and cardiovascular risk reduction
In March 2024, the FDA approved Wegovy to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. If you have a history of heart attack, stroke, or other cardiovascular disease, the cardiovascular indication may provide a separate coverage pathway through Aetna.
These additional pathways are not workarounds — they are legitimate FDA-approved indications. Your clinician must document a genuine diagnosis. At PEAK, we evaluate every patient individually and use the most appropriate clinical pathway for both treatment and coverage.
What you’ll pay
Even with Aetna coverage, your out-of-pocket cost depends on your plan’s cost-sharing structure. Here is a general breakdown of what patients typically see:
| Coverage scenario | Estimated monthly cost |
|---|---|
| Preferred formulary tier with PA approved | Plan-based copay |
| Non-preferred tier with PA approved | Plan-based copay |
| Covered after deductible | Full cost until deductible met, then copay |
| Not covered / weight loss exclusion | Cash price varies by pharmacy |
These figures are estimates and vary significantly by plan. Your actual cost depends on your deductible status, coinsurance percentage, and whether you have reached your out-of-pocket maximum.
Both manufacturers offer savings programs for eligible commercially insured patients. Novo Nordisk offers the Wegovy Savings Card and Eli Lilly offers the Zepbound Savings Program. If your insurance covers either medication, these programs may reduce your copay further. PEAK’s team can help you determine whether you qualify.
How to check your coverage
The most reliable way to confirm your Aetna coverage for Wegovy or Zepbound is to follow these steps:
- Check your formulary. Log in to your Aetna member portal and search for “semaglutide” (Wegovy) and “tirzepatide” (Zepbound) in the formulary lookup tool. Check both — your plan may cover one but not the other.
- Review your plan documents. Look for a “weight loss medication exclusion” or “anti-obesity medication” section. If your plan explicitly excludes these, coverage is unlikely regardless of medical necessity.
- Call the number on your card. Ask specifically: “Is semaglutide (Wegovy) or tirzepatide (Zepbound) covered under my plan for chronic weight management?” and “What are the prior authorization requirements?”
- Ask PEAK to verify for you. Our insurance team does this daily. We check your benefits for both medications, confirm formulary status, and identify the fastest path to approval.
What if you’re denied?
A denial is not the end of the road. If Aetna denies your prior authorization for Wegovy or Zepbound, there are several next steps:
- Peer-to-peer review. Your prescribing clinician can request a phone call with Aetna’s medical director to present your case directly. This often overturns initial denials when documentation is strong.
- Formal appeal. You have the right to appeal any PA denial. Aetna must review your appeal within specific timeframes (typically 30 days for standard appeals, 72 hours for expedited).
- Try the other medication. If Wegovy is denied, Zepbound may still be covered under a different formulary tier — or vice versa. Your clinician can submit a PA for the alternative.
- Alternative clinical pathway. If the weight management indication is denied, your clinician may explore the cardiovascular indication (Wegovy) or the sleep apnea indication (Zepbound) if clinically appropriate.
- Step therapy completion. Some Aetna plans require you to try other medications first. If you complete the required step therapy and document the results, coverage may be approved on a subsequent request.
How we help at PEAK
Insurance navigation is one of the most common barriers to starting treatment. At PEAK, we handle it before you walk through the door.
Here is what our process looks like:
- Benefits verification. We check your Aetna plan for both Wegovy and Zepbound coverage, formulary status, and any exclusions — before your first appointment.
- Prior authorization. Our clinical team prepares and submits your PA with the documentation Aetna requires. We know their criteria because we work with them regularly.
- Denial management. If your PA is denied, we manage the appeal process, including peer-to-peer reviews, formal appeals, and trying alternative medications if one is denied.
- Alternative pathways. If neither Wegovy nor Zepbound is covered, we evaluate other FDA-approved options that may be on your formulary — including Saxenda, Contrave, or phentermine.
We tell you what your insurance covers before you commit to anything. If your plan does not cover the medication you need, we will tell you that directly — along with what your options are.
Important safety information: Both Wegovy and Zepbound carry a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma) based on animal studies. They are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Discuss your full medical history with your clinician before starting treatment.
